We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New COVID-19 Rapid Antigen Test Can Be Run on Mobile Testing Platform for Lab-Quality Test Results in 15 Minutes

By LabMedica International staff writers
Posted on 08 Jan 2021
A new COVID-19 rapid antigen test that provides lab-quality test results in 15 minutes could offer a frequent, fast, cheap and easy COVID-19 screening solution to help meet the surging demand for tests and relieve the global supply chain.

Nanōmix, Inc.’s (Emeryville, CA, USA) eLab COVID-19 Rapid Antigen test is a low-cost, easy-to-use, point-of-care test that provides results in 15 minutes with lab-quality accuracy. The battery-powered, handheld device utilizes proprietary biosensor and microfluidics technologies to perform an electrochemical detection in a single-use, disposable cartridge. The Nanomix eLab is a mobile platform that can test multiple biomarkers using multiple detection methods from a single patient sample in laboratory or non-laboratory environments - so any location, including rural or remote, can have rapid, lab-quality tests for COVID-19 and a variety of other diseases and conditions. The Nanomix eLab is battery powered, portable, and easy-to-use by non-professionals in a variety of critical applications such as assisted living communities, skilled nursing facilities, emergency medical services, schools, businesses, and remote towns and villages.

Image: The Nanomix eLab® mobile testing platform (Photot courtesy of Nanōmix, Inc.)
Image: The Nanomix eLab® mobile testing platform (Photot courtesy of Nanōmix, Inc.)

The company’s eLab COVID-19 assay has also been selected as a finalist in the XPRIZE Rapid COVID Testing competition. The USD 5 million, six-month competition aims to increase COVID-19 testing capabilities 100-times past the current standard, the level of increase needed to more safely return to everyday activities.

“We are excited to be selected as a finalist in the XPRIZE Rapid COVID Testing,” said David Ludvigson, CEO of Nanomix. “The goals of the competition – to develop frequent, fast, low-cost, and easy-to-use COVID tests – align with our corporate mission. The eLab Rapid COVID Antigen test, together with our eLab Rapid COVID Antibody test, form a complete offering for COVID-19 testing.”

“Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world,” said Anousheh Ansari, CEO of XPRIZE. “XPRIZE Rapid COVID Testing competition is inspiring the best entrepreneurs and scientists to form teams and come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again.”

Related Links:
Nanōmix, Inc.


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
Rocking Shaker
HumaRock
New
Vibrio Cholerae O1/O139 Rapid Test
StrongStep Vibrio Cholerae O1/O139 Antigen Combo Rapid Test

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes